Text Size

The Effect of PinnoThin on Satiety and Food Intake

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01034605
First received: December 2, 2009
Last updated: August 29, 2012
Last verified: August 2012
History of Changes
  Purpose

Based upon an increased secretion of gastrointestinal satiety hormones (CCK, GLP-1), PinnoThin is hypothesized to be more satiating, and to limit energy intake in humans. Therefore, the objective of this study is to investigate whether PinnoThin leads to an increase in satiety as determined by VAS ratings? Additionally, does PinnoThin consumed during breakfast, in comparison to placebo, in overweight women, lead to a decrease in energy intake during an ad libitum lunch?


Condition Intervention
Obesity
 Dietary Supplement: PinnoThin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: The Effect of PinnoThin on Satiety and Food Intake

Resource links provided by NLM:

MedlinePlus related topics: Obesity
U.S. FDA Resources

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • appetite profile ratings [ Time Frame: 10 timepoints ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • energy intake [ Time Frame: 3.5 hours after PinnoThin ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: December 2008
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: inulin
oligofructose
 Dietary Supplement: PinnoThin
6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
Other Name: PinnoThin

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • age over 18 and under 45
  • women
  • BMI over 23 and under 30
  • breakfast eaters

Exclusion Criteria:

  • men
  • age under 18 and over 45
  • BMI under 23 and over 30
  • use of medication
  • pregnant and breastfeeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01034605

Locations
Netherlands
Maastricht University
Maastricht, Limburg, Netherlands, 6229ER
Sponsors and Collaborators
Maastricht University Medical Center
Investigators
Principal Investigator: Klaas R Westerterp, Prof NUTRIM
  More Information

No publications provided

Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT01034605     History of Changes
Other Study ID Numbers: HumBio_Westerterp08
Study First Received: December 2, 2009
Last Updated: August 29, 2012
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
 Overweight
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on June 18, 2013